GILEAD SCIENCES, INC.
An institutional investment manager in FOSTER CITY, CA. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 3, 2026. SEC CIK 882095.
- Reported value$1.65bn
- Positions5
Holdings: 5 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Arcus Biosciences Inc.RCUS | COM | 03969F109 | 969 | 58.8% | 31,424,760 | Unchanged | |
| Lakefront BiotherapeuticsLKFT | SPON ADR | 36315X101 | 500 | 30.3% | 16,707,477 | Unchanged | |
| Assembly Biosciences Inc.ASMB | COM NEW | 045396207 | 137 | 8.3% | 4,977,089 | Added+471,698 | |
| Kyverna Therapeutics Inc.KYTX | COM | 501976104 | 36.8 | 2.2% | 4,126,119 | Unchanged | |
| Xilio Therapeutics Inc. | COM | 98422T100 | 6.2 | 0.4% | 650,389 | Unchanged |
Sold out: 1 position
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Arcellx Inc | COM | 03940C100 | 0.0 | 0.0% | 0 | Sold out−6,720,803 |
Source: SEC EDGAR, Form 13F-HR, accession 0001123292-26-001034 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.